100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
Dapagliflozin Bromo Lactone Impurity
● In Stock
| Catalogue No.: | VL1650005 |
|---|---|
| CAS No.: | N/A |
| Mol. Formula: | C24H35BrO9 |
| Mol. Weight: | 547.43 g/mol |
Additional information on Dapagliflozin Bromo Lactone Impurity
Parent drug
DapagliflozinIUPAC Name
(2S, 3S, 4R, 5R, 6R)-2-(4-bromo-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3, 4, 5-triol compound with (S)-propane-1, 2-diol (1:1) hydrateSynonyms
N/ADescription
Dapagliflozin Bromo Lactone Impurity or (2S,3S,4R,5R,6R)-2-(4-bromo-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol compound with (S)-propane-1,2-diol (1:1) hydrate is a impurity of Dapagliflozin. Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT-2) blocker that lowers glucose levels in the blood of patients having type 2 diabetes mellitus (T2DM) by promoting glycosuria.References
Braem, Alan, et al. “Discovery and Development of Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Dapagliflozin for the Treatment of Type 2 Diabetes.†Topics in Medicinal Chemistry, 2014, pp. 73–94, https://doi.org/10.1007/7355_2014_41.?Wiviott, Stephen D., et al. “The Design and Rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial.†American Heart Journal, vol. 200, June 2018, pp. 83–89, https://doi.org/10.1016/j.ahj.2018.01.012.?Request a Quote
"*" indicates required fields
Other products related to Dapagliflozin impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
Dapagliflozin
CAS No. N/A
Cat No. VE009529
